Cellusion raises 360M JPY in series A funding


TOKYO (January 14, 2020)-, Cellusion Inc. (Headquarters, Tokyo; CEO: Shin Hatou, M.D., Ph.D., “Cellusion”) announced the completion of Series A funding raising 360M JPY. The round is mainly led by funds of Keio Innovation Initiative, Inc., DBJ Capital Co., Ltd., and SMBC Venture Capital Co., Ltd. With this fundraising, Cellusion is preparing to conduct clinical study for obtaining first in human data. Cellusion will accelerate to deliver novel regenerative therapy for all bullous keratopathy patients.

For further information: please ask us through contact form in our website.

<About Cellusion Inc.>
Cellusion Inc. is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.

Company : Cellusion Inc.
CEO : Shin Hatou, M.D., Ph.D.
Headquarter :2-4-15 Minamiaoyama, Minato, Tokyo 107-0062, JAPAN
Founded : January 2015

Back to the List